Haemacure has put itself up for sale while its hunt for financing continues to be unsuccessful. The Canadian company, which has been seeking cash since the third quarter of last year, will also suspend development of its lead candidate and reduce costs.

The Canadian biotherapeutics company Haemacure has appointed Dr Thomas Lynch to its board of directors. Dr Lynch brings 15 years experience as a research scientist in public, academic and private sectors to the position, and whilst on the board will aid the progression to Phase II/III clinical trials for Haemacure's lead candidate, Hemaseel HMN (fibrin sealant), for biosurgical haemostasis. Dr Lynch currently serves as senior vice-president of compliance, regulatory affair and public policy for Talecris Biotherapeutics; prior to this he was vice-president of regulatory affair and quality assurance at CryoLife.

Renovo's scar-healing treatment Juvista (human recombinant TGF beta3) has succeeded in a Phase II study, but details of US development plans for the product have disappointed analysts and investors.

Renovohas received positive feedback from the EU's CHMPregarding its plans for Phase III development of the scar-reduction treatment Juvista.